📇 Rhumatologue · AMBOISE · (37) · Libéral

M Olivier ARNAUD

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Praticien-chercheur
18 articles scientifiques publiés — formation continue solide
Cabinet de groupe — continuité de soins
Plusieurs praticiens dans le même cabinet — un confrère peut prendre le relais en cas d'absence
Disponibilité géographique
8 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
131.9 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 AMBOISE (37)LibéralRPPS 10002028297

🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

Direct dating of brittle extensional deformation in the internal zones of the Rif Chain
2021
Congrès27e édition de la Réunion des Sciences de la Terre

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial

European journal of heart failure · 2017

📚 86 citations🎯 RCR 3.24Top 15% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Aims An excessive production of aldosterone influences outcome in patients with heart failure (HF) and in obese patients. Findings from laboratory studies suggest that chronic aldosterone blockade maybe more beneficial in abdominally obese HF-prone rats. In the current study, we investigated if the clinical response to a mineralocorticoid receptor antagonist in mildly symptomatic HF patients varied by abdominal obesity. Methods and results A total of 2587 NYHA class II, reduced ejection fraction HF (HFrEF) patients enrolled in the EMPHASIS-HF trial were randomly assigned to eplerenone and placebo. In this post hoc analysis, patients were categorized according to waist circumference (WC) (normal if WC &lt; 102 cm in men and &lt; 88 cm in women; abdominal obesity if WC ≥ 102 cm in men and ≥ 88 cm women). The potential statistical interaction between the treatment and WC was assessed on the primary endpoint of death from cardiovascular causes or hospitalization for HF and other secondary endpoints. Over a median follow-up of 21 months, a significant benefit of eplerenone for the primary outcome was noted in both normal [hazard ratio (HR) 0.77, 95% confidence interval (CI) 0.61–0.98, P = 0.03] and increased (HR 0.48, 95% CI 0.37–0.63, P &lt; 0.0001) WC subgroups, but the latter patients appeared to receive greater benefit than patients with normal WC (P for interaction = 0.01). This suggests a significant quantitative (treatment effect varies in magnitude by subgroup, but is always in same direction) rather than a qualitative interaction (direction of the treatment effect varies by subgroup) between eplerenone and WC in the adjusted analysis. Mean doses of eplerenone, blood pressure and serum potassium changes and adverse events were similar between WC subgroups. Conclusion In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity. The findings are potentially hypothesis generating and need to be replicated in other HFrEF populations.

Reproducibility in echocardiographic assessment of diastolic function in a population based study (the STANISLAS Cohort study)

PloS one · 2015

📚 46 citations🎯 RCR 1.76🔓 Open Access📄 PDF gratuit ↗

Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation

European journal of heart failure · 2016

📚 42 citations🎯 RCR 1.42🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background Atrial flutter-related tachycardiomyopathy (AFL-TCM) is a rare and treatable cause of heart failure. Little is known about its epidemiology and long-term prognosis. Our aims are to determine the prevalence, predictors and outcomes of AFL-TCM. Methods and results A total of 1269 patients were referred for radiofrequency ablation of AFL between January 1996 and September 2014; 184 had reduced left ventricular ejection fraction (LVEF &lt;40%). At 6 months after AFL ablation, 103 patients (8.1% of the population, 56% of patients with baseline LVEF &lt;40%) had marked LVEF improvement: these were considered to have AFL-TCM. Patients with persisting reduced LVEF were considered to have systolic dysfunction unrelated to AFL. Patients were followed for a median (percentile25–75) of 1.15 (0.4–2.8) years. Patients with AFL-TCM were younger, had lower prevalence of ischaemic cardiomyopathy and used less antiarrhythmic drugs than patients with systolic dysfunction unrelated to AFL. In multivariable analysis, ischemic cardiomyopathy [odds ratio (OR) = 0.32, 95% confidence interval (CI) 0.15–0.68) P = 0.003] and prescription of antiarrhythmic drug before ablation [OR = 0.41, 95% CI 0.20–0.84, P = 0.02] were significantly associated with a lower probability of LVEF improvement during follow-up. Patients with AFL-TCM had similar survival to patients without systolic dysfunction at baseline [hazard ratio (HR) = 0.96 95% CI 0.34–2.65, P = 0.929], whereas patients with systolic dysfunction unrelated to AFL had higher mortality rates compared with patients without systolic dysfunction at baseline [HR = 2.88, 95% CI 1.45–5.72, P = 0.002]. Conclusions Marked LVEF improvement was observed in 56% of patients with baseline LVEF &lt;40% at 6 months after ablation. These patients had similar survival to patients without baseline systolic dysfunction, whereas patients who remained with LVEF &lt;40% had a threefold increase in mortality rates.

Cookies & analyse de trafic

M Olivier ARNAUD

Pourquoi vous devez consulter ce praticien

Publications académiques en France

Lieux de consultation(8)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (18) — classées par pathologie

Transversal6

Épidémiologie & registres5

Pédiatrie3

Pharmacovigilance2

Activité physique / Rééducation1

Case report / série1

Essai clinique1

Gériatrie1

Partager cette fiche